内容紹介
Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF
Summary
The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF). The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10). The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; χ2 test). In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group. In both groups, 3 cases(30%)of vomiting were observed. However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group. These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.
要旨
口腔癌に対してdocetaxel,nedaplatinあるいはcisplatin(5日間連日投与),5-fluorouracil(TPF)3剤併用化学療法を実施した患者を対象にaprepitantおよびfosaprepitantによる制吐効果を検討した。初日から3日間aprepitantを経口投与する群(APR群),初日のみfosaprepitantを静脈内投与する群(FOS群)とした。その結果,悪心頻度はAPR群60%,FOS群で90%であり,APR群では2日以上継続する悪心の頻度が有意(p=0.02,χ2 test)に低かった。また,累積悪心スコア(ACU: 悪心グレード×日数)の値もAPR群のほうが低い傾向にあった。両群とも嘔吐が30%にみられたが,連日に及ぶ嘔吐の頻度もAPR群で低い傾向にあった。以上より,プラチナ製剤連日投与レジメンに対する制吐療法では,初日のみのfosaprepitant静脈内投与に比べて,3日間のaprepitant経口投与がより効果的であることが示唆された。
目次
Summary
The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF). The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10). The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; χ2 test). In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group. In both groups, 3 cases(30%)of vomiting were observed. However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group. These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.
要旨
口腔癌に対してdocetaxel,nedaplatinあるいはcisplatin(5日間連日投与),5-fluorouracil(TPF)3剤併用化学療法を実施した患者を対象にaprepitantおよびfosaprepitantによる制吐効果を検討した。初日から3日間aprepitantを経口投与する群(APR群),初日のみfosaprepitantを静脈内投与する群(FOS群)とした。その結果,悪心頻度はAPR群60%,FOS群で90%であり,APR群では2日以上継続する悪心の頻度が有意(p=0.02,χ2 test)に低かった。また,累積悪心スコア(ACU: 悪心グレード×日数)の値もAPR群のほうが低い傾向にあった。両群とも嘔吐が30%にみられたが,連日に及ぶ嘔吐の頻度もAPR群で低い傾向にあった。以上より,プラチナ製剤連日投与レジメンに対する制吐療法では,初日のみのfosaprepitant静脈内投与に比べて,3日間のaprepitant経口投与がより効果的であることが示唆された。